RhumbLine Advisers’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-63,356
| Closed | -$117K | – | 4411 |
|
|
2023
Q1 | $117K | Buy |
63,356
+290
| +0.5% | +$359 | ﹤0.01% | 2835 |
|
|
2022
Q4 | $70K | Sell |
63,066
-63
| -0.1% | -$90 | ﹤0.01% | 2932 |
|
|
2022
Q3 | $148K | Buy |
63,129
+5,688
| +10% | +$20.1K | ﹤0.01% | 2952 |
|
|
2022
Q2 | $174K | Buy |
57,441
+14,406
| +33% | +$70.1K | ﹤0.01% | 2968 |
|
|
2022
Q1 | $292K | Sell |
43,035
-1,683
| -4% | -$12K | ﹤0.01% | 2650 |
|
|
2021
Q4 | $373K | Buy |
44,718
+2,145
| +5% | +$17.7K | ﹤0.01% | 2627 |
|
|
2021
Q3 | $316K | Buy |
42,573
+1,167
| +3% | +$7.23K | ﹤0.01% | 2747 |
|
|
2021
Q2 | $282K | Buy |
41,406
+13,559
| +49% | +$113K | ﹤0.01% | 2818 |
|
|
2021
Q1 | $286K | Sell |
27,847
-1,050
| -4% | -$11.5K | ﹤0.01% | 2717 |
|
|
2020
Q4 | $202K | Buy |
28,897
+3,635
| +14% | +$28.3K | ﹤0.01% | 2835 |
|
|
2020
Q3 | $206K | Sell |
25,262
-3,807
| -13% | -$23.6K | ﹤0.01% | 2674 |
|
|
2020
Q2 | $201K | Buy |
29,069
+1,334
| +5% | +$7.2K | ﹤0.01% | 2771 |
|
|
2020
Q1 | $132K | Buy |
27,735
+2,430
| +10% | +$14K | ﹤0.01% | 2713 |
|
|
2019
Q4 | $221K | Buy |
25,305
+276
| +1% | +$1.49K | ﹤0.01% | 2717 |
|
|
2019
Q3 | $83K | Buy |
25,029
+2,094
| +9% | +$8.38K | ﹤0.01% | 2906 |
|
|
2019
Q2 | $114K | Buy |
22,935
+3,345
| +17% | +$17.8K | ﹤0.01% | 2910 |
|
|
2019
Q1 | $121K | Buy |
19,590
+439
| +2% | +$2.12K | ﹤0.01% | 2836 |
|
|
2018
Q4 | $65K | Buy |
19,151
+5,410
| +39% | +$25.3K | ﹤0.01% | 2923 |
|
|
2018
Q3 | $89K | Sell |
13,741
-1,000
| -7% | -$7.43K | ﹤0.01% | 2879 |
|
|
2018
Q2 | $113K | Buy |
14,741
+1,924
| +15% | +$27.7K | ﹤0.01% | 2860 |
|
|
2018
Q1 | $286K | Buy |
12,817
+2,325
| +22% | +$51.6K | ﹤0.01% | 2457 |
|
|
2017
Q4 | $134K | Buy |
+10,492
| New | +$154K | ﹤0.01% | 2730 |
|
Other funds holding JNCE
RhumbLine Advisers's JNCE Position: Q2 2023 in Review
RhumbLine Advisers sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 63,356 shares — an estimated $117K sold.
RhumbLine Advisers first reported a position in JNCE in Q4 2017 and held it in 22 quarters. The position peaked at $373K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- RhumbLine Advisers reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- RhumbLine Advisers sold 63,356 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $117K.
- RhumbLine Advisers first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2017 and held it in 22 quarters.
- RhumbLine Advisers's Jounce Therapeutics, Inc. Common Stock position peaked at $373K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.